On August 25, 2020 Shenzhen Yuce Biological reported that completed a $43 million Series C round led by Yuanzhi Science & Technology Medical for its clinical testing of cancer immunotherapies (Press release, Shenzhen Yuce Biotechnology, AUG 25, 2020, View Source [SID1234564010]). Yuce Bio has developed a new antigen detection and identification platform, a professional database for cancer immunology based on bioinformatics, and a large real-world research database of tumor immunodiagnosis. As part of its program, Yuce has developed YuceOne Plus, the first in vitro diagnostic reagent that uses gene testing to evaluate the effectiveness of an immunotherapy drug regimen.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!